nach oben

Erschienen in:

Open Access 01.12.2020 | Research article

Folate levels in hepatocellular carcinoma patients with portal vein thrombosis

verfasst von: Giulia Malaguarnera, Vito Emanuele Catania, Saverio Latteri, Antonio Maria Borzì, Gaetano Bertino, Roberto Madeddu, Filippo Drago, Michele Malaguarnera

Erschienen in: BMC Gastroenterology | Ausgabe 1/2020

Abstract

Background

Portal vein thrombosis (PVT) occurs frequently in hepatocellular carcinoma (HCC) and is often diagnosed in the course of a routine patient evaluation and surveillance for liver cancer. The purpose of this study is to investigate the relationship between folate status and portal vein thrombosis.

Methods

HCC with PVT patients were 78, HCC without PVT were 60 and control subjects were 70 randomly selected. We evaluate serum and red blood cellular folate, homocysteine, alpha fetal protein cholesterol, triglycerides, prothrombin time.

Results

HCC patients with PVT showed lower levels of serum folate, respect HCC patients without PVT, with an average difference of 1.6 nmol/l p < 0.01 (95% CI − 2.54 to − 0.66), red cell folate 33.6 nmol/l p < 0.001 (95% CI − 43.64 to − 23.55) and albumin 0.29 g/dl p < 0.001 (95% CI − 0.42 to − 0.15); PVT patients displayed higher levels of bilirubin 0.53 mg/dl p < 0.001 (95% CI 0.23 to 0.78), INR 0.91 p < 0.001 (95% CI 0.72 to 1.09), γGT 7.9 IU/l (95% CI 4.14 to 11.65) and homocysteine 4.6 μmol/l p < 0.05 (95% CI 0.32 to 8.87)

Conclusion

The low folate concentration and higher levels of homocysteine are associated with the loss of antithrombotic function, and with a more aggressive course of HCC and with a higher change of complications related to portal vein thrombosis

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

PVT

Portal vein thrombosis

HCC

Hepatocellular carcinoma

γGT

γ-Glutamyltransferase

DNA

Deoxyribonucleic acid

αFP

Alpha-fetoprotein

Computed tomography

Magnetic resonance

CLIP

Cancer Liver Italian Program score

TNM

(Tumour Nodes Metastases) Classification of Malignant Tumours

Ultrasonography

°C

Degree Celsius

Gravitational acceleration

RBC

Red blood cellular folate

tHcy

Total homocysteine

HHcy

Hyperhomocysteine

HCV

Hepatitis C virus

HCB

Hepatitis B virus

INR

International normalized ratio

AST

Aspartate transaminase

ALT

Alanine transaminase

BMI

Body Mass Index

HDL

High-density lipoprotein

LDL

Low-density lipoprotein

Nitroxide

Background

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer mortality [1].

There are striking variations in its incidence in various parts of the world, although the 83% of the total deaths occur in developing countries [2, 3].

Many studies have focused on the investigation of markers to predict the outcomes of HCC and to exploring accurate prognostic factors for the clinical examination [4, 5]. Many HCC patients display portal hypertension, which cause the blood flow velocity of the portal vein to slow down. Changes in haemodynamic of the portal vein are the anatomical base of Portal Vein Thrombosis (PVT) formation. This complication is a multifactorial process, characterized also by the increase of systemic prothrombotic factors and the presence of local inflammatory foci. As a result, there is hypercoagulation, accompanied by the slowing of blood flow and damage to the vessel walls [6‐8].

Patients with HCC with PVT have poor prognoses than those without PVT [9‐11].

Evidence show a relationship between nutrition and environmental factors in relation to the progression of HCC. For instance, folate (known also as vitamin B9) and its derivatives are found abundantly in leafy green vegetable and fresh fruit. These compounds play an essential role in the production and maintenance of new cells and is involved in DNA methylation, DNA synthesis and DNA repair.

Folate is a water-soluble beta-vitamin critical for health. It participates in numerous single-carbon exchange reactions that are essential for the synthesis of nucleotides purine/pyrimidine. Folates have been studied as a potential chemo-preventive agent.

Dietary folate is digested in the jejunal brush border surface by intestinal glutamate carboxy peptidase, followed by the transfer, through the portal vein to the liver where it is transported across membranes by the reduced folate carrier, possibly together with folate binding protein or the proton coupled folate transporter. These molecules are mainly stored in the liver, where are used in several reaction. Then, dietary folate is transported to the systemic blood circulation and in part, eliminated by the biliary excretion [12].

Both dietary and endogenous folate plays an important role in epigenetic methylation reactions, in lipid export, antioxidant defence and the hepatic methionine metabolism, which in turn regulates homocysteine levels [13, 14].

The objective of our study is to investigate, the relationship among blood folate and PVT in HCC patients, comparing these variables in controls subjects and in patients with and without PVT.

Methods

Patients recruitment

The subject with HCC included in this study were 138 patients with HCC: 78 HCC with PVT (31 females and 47 males) aged 65 or more years, and 60 HCC without PVT (24 female and 36 males), aged 60 or more years, living in Sicily (Italy).

The control subjects were 70 (35 female/35 males), aged 60 years or more. They were randomly selected and healthy without any history of cancer, major organ failure or active intravenous drug abuse.

The inclusion criteria were patients older than 18, with histologically proven HCC and with written informed consent.

This study used similar recruitment strategies, inclusion and exclusion criteria and measurement protocol adopted in previous studies on HCC patients with PVT and in controls subjects.

The questionnaires were administered by trained interview and focused on dietary, sociodemographic, environmental and lifestyle information.

Serum and whole blood folate assay

Serum and whole blood samples were collected into citrate tubes during the screening visit. They were immediately put on ice and centrifuged (2000×g, 4 °C, 10 min) within 60 min. Both serum and whole blood samples were stored at − 70 °C until analysis and were measured using QuantaPhase radioassay II Kit (Bio-Rad Laboratories, Hercules, California).

Statistical analysis

Data were expressed as mean ± standard deviation. To assess relationship and differences between folate, Hcy, alfa-fetoprotein of different patent groups, parametric, non-parametric Fisher's exact test and 95% CI Odds Ratio (O.R.) Baptista–Pike method or ordinary one-way ANOVA with Tukey's multiple comparisons test. A p value < 0.05 was considered statistically significant. Data were analysed using the GraphPad Prism 8 statistical software package (8.4.2 Macintosh Version; GraphPad Software San Diego, CA).

Univariate and multivariate linear regression were built to assess the relationship between folate concentration and sociodemographic data, area of residence (urban, metropolitan, semi urban, rural), social class (managers, skilled, semiskilled, unskilled) and clinical features of HCC patients.

Results

PVT patients’ ages ranged between 60 years and over; of these 35.90% were smokers, 12.82% were diabetics, 12.82% complained of renal failure; 15.38% of Hypertension; 23.08% of cardiovascular disease; 19.23% of dyspepsia, 12.82% experienced alcohol consumption. Etiologic factors in PVT patients were 44.87% for HCV, 32.5% for HBV and 10.26% unknown (Tables 1 and 2).

Table 1

Demographic and baseline characteristics of the study population

	With PVT	NPVT	Controls	PVT versus NPVT		PVT versus Control		NPVT versus Control
	78 pt	60 pt	70 pt	p value	95% CI	p value	95% CI	p value	95% CI
Age (range)	60–75	60–75	60–75	–	–	–	–	–	–
Female/male	31/47	24/36	35/35	> 0.9999	0.5042 to 1.968	0.2475	0.3352 to 1.275	0.2913	0.3264 to 1.326
BMI (Kg/m²)	23.8 ± 4.4	25.0 ± 4.2	24.7 ± 4.2	0.2336	− 2.934 to 0.5336	0.409	− 2.562 to 0.7621	0.9161	− 1.476 to 2.076
Systolic blood pressure (mmHg)	140.2 ± 11.4	137.0 ± 12.8	140.1 ± 14.9	0.3293	− 2.097 to 8.497	0.9988	− 4.978 to 5.178	0.3700	− 8.527 to 2.327
Diastolic blood pressure (mmHg)	82.2 ± 8.4	81.8 ± 9.2	81.4 ± 9.7	0.9644	− 3.283 to 4.083	0.8543	− 2.731 to 4.331	0.9661	− 3.373 to 4.173
Heart rate (b.p.m)	83.7 ± 9.68	83.8 ± 9.7	81.4 ± 10.2	0.9981	− 4.099 to 3.899	0.3344	− 1.534 to 6.134	0.3517	− 1.697 to 6.497

CI, confidence interval; pt, patients; bpm, beats per minute; BMI, Body Mass Index

Table 2

Characteristics of the patients and risk factors

	With PVT = 78 pt		NPVT = 60 pt		Controls = 70 pt		PVT versus NPVT			PVT versus control			NPVT versus control
	N	%	N	%	N	%	p	95% CI O.R.	Sig	p	95% CI O.R.	Sig	p	95% CI O.R.	Sign
Smokers/no smokers	28	35.90	27	45.00	20	28.57	0.2975	0.3451 to 1.347	ns	0.3821	0.7087 to 2.877	ns	0.0672	0.9742 to 4.156	ns
Diabetes mell	10	12.82	9	15.00	8	11.43	0.8049	0.3208 to 2.078	ns	> 0.9999	0.4387 to 3.093	ns	0.6078	0.5114 to 3.884	ns
Hypertension	12	15.38	14	23.33	10	14.29	0.2757	0.2682 to 1.431	ns	> 0.9999	0.4575 to 2.783	ns	0.2569	0.7175 to 4.602	ns
Renal failure	10	12.82	12	20.00	12	17.14	0.3484	0.2274 to 1.425	ns	0.4952	0.2786 to 1.697	ns	0.8211	0.5195 to 2.809	ns
Cardiovascular dis	18	23.08	16	26.67	10	14.29	0.6921	0.3726 to 1.791	ns	0.2096	0.8020 to 4.219	ns	0.1226	0.9064 to 5.360	ns
Dyspepsia	15	19.23	21	35.00	12	17.14	0.0501	0.2122 to 0.9495	ns	0.8325	0.5049 to 2.610	ns	0.026	1.132 to 5.798	*
Alcohol	10	12.82	16	26.67	0	0	0.0489	0.1659 to 0.9651	*	0.0016	–	**	< 0.0001	–	****
HCV	35	44.87	25	41.67	0	0	0.732	0.5902 to 2.235	ns	< 0.0001	–	****	< 0.0001	–	****
HBV	25	32.05	9	15.00	0	0	0.028	1.135 to 6.349	*	< 0.0001	–	****	0.0007	–	***
HCC unknown aetiology	8	10.26	10	16.67	0	0	0.3132	0.2084 to 1.480	ns	0.007	–	**	0.0003	–	***

Fisher's exact test, 95% CI Odds Ratio (O.R.) Baptista–Pike method

pt, patients; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HBV, hepatitis B virus

Summary: *< 0.05; **< 0.005; ***< 0.001; ****< 0.0001

HCC without PVT patient’s ages ranged 60 years and over; of these 45% were smokers or previous smokers, 15% were diabetics, 23.33% complained of hypertension, 26.67% of cardiovascular disease, 20% of renal failure, 35% of dyspepsia, 26.67% of alcohol consumption. Etiologic factors were 41.67% HCV, 15% HBV, 16,67% unknown.

In the control group ages ranged between 60 years and over; of these 28.57% were smokers, 11.43% were diabetics, 14.29% complained of hypertension, 14.29% of cardiovascular disease, 17.14% of renal failure, 17.14% of dyspepsia (Tables 1 and 2).

Comparison from HCC patients with PVT to HCC patients without PVT

We observed that were lower serum folate 1.6 nmol/l p < 0.01 (95% CI − 2.54 to − 0.66), red cell folate 33.6 nmol/l p < 0.001 (95% CI − 43.64 to − 23.55), albumin 0.29 g/dl p < 0.001 (95% CI − 0.42 to − 0.15); were higher bilirubin 0.53 mg/dl p < 0.001 (95% CI 0.23 to 0.78), INR 0.91 p < 0.001 (95% CI 0.72 to 1.09), γGT 7.9 IU/l (95% CI 4.14 to 11.65) and homocysteine 4,6 μmol/l p < 0.05 (95% 0.32 to 8.87) (Table 3).

Table 3

Laboratory parameters and classifications of subjects included in the study

	PVT (n = 78)	NPVT (n = 60)	Controls (n = 70)	PVT versus NPVT(p value)	PVT versus Controls (p value)	NPVT versus Controls (p value)
Bilirubin (mg/dl)	2.87 ± 0.6	2.36 ± 1.02	1.24 ± 0.38	< 0.001	< 0.001	< 0.001
Albumin (g/dl)	3.15 ± 0.42	3.44 ± 0.38	3.96 ± 0.55	< 0.001	< 0.001	< 0.001
INR	2.91 ± 0.54	2.00 ± 0.57	1.22 ± 0.36	< 0.001	< 0.001	< 0.001
Tot cholesterol (mmol/l)	5.77 ± 1.08	5.69 ± 1.01	5.50 ± 1.04	0.659	0.124	0.297
HDL (mmol/l)	1.40 ± 0.36	1.41 ± 0.37	1.46 ± 0.40	0.873	0.338	0.463
LDL (mmol/l)	3.44 ± 0.38	3.48 ± 0.39	3.46 ± 0.37	0.545	0.747	0.765
Triglycerides (mmol/l)	1.57 ± 0.70	1.50 ± 0.68	1.48 ± 0.65	0.556	0.421	0.864
ALT (IU/l)	51.20 ± 10.80	48.20 ± 11.90	34.50 ± 10.20	0.124	< 0.001	< 0.001
AST (IU/l)	49.20 ± 10.60	48.70 ± 10.80	33.10 ± 10.80	0.786	< 0.001	< 0.001
γGT (IU/l)	82.80 ± 10.20	74.90 ± 12.10	27.40 ± 10.80	< 0.001	< 0.001	< 0.001
AFP (mg/l)	236.10 ± 15.80	240.20 ± 14.20	3.20 ± 0.60	0.117	< 0.001	< 0.001
Serum folate (nmol/l)	5.24 ± 2.81	6.84 ± 2.71	8.50 ± 3.01	< 0.001	< 0.001	0.001
Red cell folate (nmol/l)	144.20 ± 30.60	177.80 ± 28.20	294.20 ± 27.80	< 0.001	< 0.001	< 0.001
Total homocysteine (μmol/l)	32.80 ± 12.20	28.20 ± 13.10	10.70 ± 6.90	0.035	< 0.001	< 0.001

PVT, portal vein thrombosis; INR, International normalized ratio; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ALT, alanine transferase; AST, aspartate transferase, γGT, gamma-glutamil-tranferase

Comparison between HCC patients with PVT and controls

We observed that were lower serum folate 3.28 nmol/l p < 0.001 (95% CI − 4.20 to − 2.31), red cell folate 150 nmol/l p < 0.001 (95% CI − 159.53 to − 140.46), albumin 0.83 g/dl p < 0.001 (95% CI − 0.96 to − 0.65); were higher bilirubin 1.63 mg/dl p < 0.001(95% CI 1.46 to 1.79), INR 1.69 p < 0.001 (95% CI 1.54 to 1.84) ALT 16.70 IU/l p < 0.001 (95% CI 13.27 to 20.11) AST 16 IU/l p < 0.001 (95% CI 12.62 to 19.58) γGT 55.4 IU/l p < 0.001 (95% CI 51.28 to 58.81), αFP 232.9 mg/l p < 0.001 (95% CI 229.16 to 236.63) and homocysteine 22.10 μmol/l p < 0.001 (95% CI 51.28 to 58.81). The results are showed in Table 3

Comparison between HCC patients without PVT and controls (Table 3)

We observed that serum folate was lower 1.66 nmol/l p < 0.001 (95% CI − 2.66 to − 0.66), red cell folate 116.4 nmol/l p < 0.001 (95% CI − 126.14 to − 106.66), Albumin 0.52 g/dl p < 0.001 (95% CI − 0.68 to − 0.35); Bilirubin was higher 1.12 mg/dl p < 0.001(95% CI 0.86 to 1.38), INR 0.78 p < 0.001 (95% CI 0.61 to 0.94) ALT 13.70 IU/l p < 0.001 (95% CI 9.86 to 17.53) AST 15.60 IU/l p < 0.001 (95% CI 11.84 to 19.36) γGT 47.50 IU/l p < 0.001 (95% CI 43.52 to 51.47), αFP 237.00 mg/l p < 0.001 (95% CI 233.64 to 240.36), total homocysteine 17.50 μmol/l p < 0.001 (95% CI 13.93 to 21.06).

The median value of serum folate levels was 5.9 nmol/l. Patient were divided into two groups each of 69 patients (Table 4): ≤ 5.9 nmol/l and > 5.9 nmol/l.

Table 4

Clinical features of the HCC patients

	Serum folate				p value	Signif	Odds-ratio	95% CI O.R.
	≤ 5.9 mm/l (69 pt)		> 5.9 mm/l (69 pt)
	N	%	N	%
PVT	44	63.77	34	49.28	0.1219	ns	1.812	0.9335 to 3.584
HCC stage I	16	23.19	20	28.99	0.5612	ns	0.7396	0.3337 to 1.573
HCC stage II	18	26.09	23	33.33	0.4564	ns	0.7059	0.3412 to 1.519
HCC stage III	20	28.99	21	30.43	> 0.9999	ns	0.9329	0.4610 to 1.876
HCC stage IV	15	21.74	5	7.25	0.0276	*	3.556	1.265 to 9.289
Clip Score 0–2	31	44.93	28	40.58	0.7309	ns	1.195	0.6229 to 2.310
Clip Score 3–6	38	55.07	41	59.42	0.7309	ns	0.8371	0.4329 to 1.605
Cirrhosis	25	36.23	33	47.83	0.2272	ns	0.6198	0.3139 to 1.194
< 50 mm	25	36.23	33	47.83	0.2272	ns	0.6198	0.3139 to 1.194
> 50 mm	44	63.77	36	52.17	0.2272	ns	1.613	0.8373 to 3.185
Tumour Invasion	26	37.68	32	46.38	0.3886	ns	0.6991	0.3570 to 1.345
Vascular Invasion	29	42.03	31	44.93	0.8637	ns	0.8887	0.4619 to 1.701
Extra-hepatic MTS	44	63.77	29	42.03	0.0166	*	2.428	1.190 to 4.875

PVT, portal vein thrombosis; HCC, hepatocellular carcinoma; Mtd, max tumour diameter

Summary:*< 0.05; **< 0.005; ***< 0.001; ****< 0.0001

We observed deficient serum folate levels in PVT patients in high grade (IV stage) of HCC (p = 0.028) and in presence of extrahepatic metastases (p = 0.016) (Table 4).

To identify the prognostic factors of PVT both univariate and multivariate analyses were used to evaluate red cellular folate and other clinical pathological variables.

The results suggested that red cellular folate (p < 0.01), higher homocysteine level (p < 0.01) and higher AFP (p < 0.05) were related to PVT. The other variables included in multivariate models were not statistically significant.

Discussion

Serum folate, RBC folate and plasma total Hcy are the three most used biochemical indicators to assess folate status [15].

In our study we observed that serum folate and red cells folate in HCC patients with PVT were lower than in no PVT and controls subjects, whereas homocysteine was higher than in no PVT and in control subjects. These conditions induce atherosclerotic and thrombotic vascular disorders and promote oxidative stress, inflammation and endothelial injury, as well prothrombotic effect. Portal vein thrombosis is a relatively frequent event in cirrhosis and HCC, where its incidence varies from 7.4 to 17.8% in different studies [16‐18].

In PVT, the concentration of folate in red cells result as a strong indicator of folate status, because the transitory changes of the diet do not control it. The concentration of folate in red cells is much higher than in plasma. Moreover, its concentration is established during erythropoiesis, for this reason its levels last for approximately 4 months [19].

The patients with PVT and HCC display an aggressive disease course, worsening of liver conditions, complications related to portal hypertension, low tolerance to treatment and lower serum folate and HHCy if compared with HCC subject without PVT [20‐23].Numerous variables such as agents, drugs, diseases and lifestyle factors have a relevant impact on folate status. Especially those substance that act directly or indirectly on enzymes where folates operate as cofactors, but also as a consequence of the increase of disulphide exchange reactions, or the impairment of folate absorption. In fact, folate deficiency may be caused by the inadequate intake, the reduced absorption from the gastrointestinal tract, or by increased drug consumption and interactions. Subjects without a balanced diet, patients with renal disease, inflammatory bowel disease or malignant disease are more at risk for folate deficiency and, as a consequence, they have elevated levels homocysteine [24‐29].

The role of folate deficiency and the hyperhomocysteinemia in PVT and in venous thromboembolism deserve also a relevant attention to evaluate the role of these findings in the pre-operative, operative and post-operative thrombotic complication of HCC.

PVT prophylaxis with anticoagulants is still controversial and relatively less investigated; for this reason, it can be recommended on an individual basis. Despite these results, the reduction of thromboembolism with folate supplementation in patients with PVT and HCC is scarce [30‐32].

The identification of the high-risk patients with hypofolatemia and/or hyper homocysteinemia, through the evaluation of genetic mutation and nutritional deficiency is essential to plan clinical management in subjects who are candidate for major surgery or liver transplantation [33].

Folate carry out their metabolic functions when it is converted to 5-methyl tetrahydrofolate-. 5-methyltetrahydrofolate and it is associated with improvements in NOS coupling and nitroxide (NO) synthesis in vivo [34‐38].

NO is a potent vasodilator that improves vascular function through its anti-inflammatory, antithrombotic and anti-angiogenic properties.

The study has established an inverse association between the folate level and tumour size, multiplicity and metastases; disease progression was categorized into stages 1 to 4, and serum folate decreased as disease stage progressed [39‐43] (Table 4).

Therefore, folate deficiency aids the incorporation of uracil into DNA, which can lead to DNA breaks and chromosome instability; such breaks could contribute to the increased risk of cancer [44‐49].

Conclusion

Our study supports the hypothesis that the folate status shows a protective role in HCC prevention, development and prognosis.

Further longitudinally designed and interventional studies with a large sample size may help to determine the optimal strategies to improve folate status of HCC patients [50] and to evaluate the effects in coagulation disorders in HCC patients with PVT [51].

Acknowledgements

Not applicable.

The study protocol was approved by the Human Ethics Review Committee of Cannizzaro Hospital and a signed consent form was obtained from each patient. Study recruitment was performed in observation and respect of Helsinki Declaration. All patients gave their written informed consent for the study participation and consent for the publication.

Not applicable.

Competing interests

All authors declare that they have no competing interests.

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Bertino G, Malaguarnera G, Frazzetto E, Sciuto A, Inserra G, Zanghì GN, Malaguarnera M. Responsibility of hepatitis C virus in the development of hepatocellular carcinoma: from molecular alterations to possible solutions. World J Hepatol. 2018;10(6):448–51.PubMedPubMedCentralCrossRef

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMedCrossRef

Kao JH, Chen DS. Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. Liver Int. 2005;25(4):696–703.PubMedCrossRef

Malaguarnera M, Latteri S, Bertino G, Madeddu R, Catania VE, Currò G, Borzì AM, Drago F, Malaguarnera G. D-dimer plasmatic levels as a marker for diagnosis and prognosis of hepatocellular carcinoma patients with portal vein thrombosis. Clin Exp Gastroenterol. 2018;11:373–80.PubMedPubMedCentralCrossRef

Latteri S, Malaguarnera G, Catania VE, La Greca G, Bertino G, Borzì AM, Drago F, Malaguarnera M. Homocysteine serum levels as prognostic marker of hepatocellular carcinoma with portal vein thrombosis. Curr Mol Med. 2019;19(7):532–8.PubMedCrossRef

Galvano F, Malaguarnera M, Vacante M, Motta M, Russo C, Malaguarnera G, D’Orazio N, Malaguarnera L. The physiopathology of lipoprotein (a). Front Biosci (Schol Ed). 2010;2:866–75.

Sogaard KK, Astrup LB, Vilstrup H, Gronbaek H. Portal vein thrombosis; risk factors, clinical presentation and treatment. BMC Gastroenterol. 2007;7:34.PubMedPubMedCentralCrossRef

Malaguarnera G, Gagliano C, Salomone S, et al. Folate status in type 2 diabetic patients with and without retinopathy. Clin Ophthalmol. 2015;9:1437–42.PubMedPubMedCentralCrossRef

Lucock M. Folic acid: nutritional biochemistry, molecular biology, and role in disease processes. Mol Genet Metab. 2000;71(1–2):121–38.PubMedCrossRef

10.

Rampersaud GC, Kauwell GP, Hutson AD, Cerda JJ, Bailey LB. Genomic DNA methylation decreases in response to moderate folate depletion in elderly women. Am J Clin Nutr. 2000;72(4):998–1003.PubMedCrossRef

11.

Duthie SJ, Narayanan S, Blum S, Pirie L, Brand GM. Folate deficiency in vitro induces uracil misincorporation and DNA hypomethylation and inhibits DNA excision repair in immortalized normal human colon epithelial cells. Nutr Cancer. 2000;37(2):245–51.PubMedCrossRef

12.

Kim YI. Folate and colorectal cancer: an evidence-based critical review. Mol Nutr Food Res. 2007;51(3):267–92.PubMedCrossRef

13.

Medici V, Halsted CH. Folate, alcohol, and liver disease. Mol Nutr Food Res. 2013;57(4):596–606.PubMedCrossRef

14.

Malaguarnera G, Gagliano C, Giordano M, et al. Homocysteine serum levels in diabetic patients with non proliferative, proliferative and without retinopathy. Biomed Res Int. 2014;2014:191497.PubMedPubMedCentralCrossRef

15.

Creus M, Deulofeu R, Peñarrubia J, Carmona F, Balasch J. Plasma homocysteine and vitamin B12 serum levels, red blood cell folate concentrations, C677T methylenetetrahydrofolate reductase gene mutation and risk of recurrent miscarriage: a case–control study in Spain. Clin Chem Lab Med. 2013;51(3):693–9.PubMedCrossRef

16.

Francoz C, Belghiti J, Vilgrain V, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut. 2005;54(5):691–7.PubMedPubMedCentralCrossRef

17.

Villa E, Cammà C, Marietta M, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143(5):1253-1260.e4.PubMedCrossRef

18.

Abdel-Razik A, Mousa N, Elhelaly R, Tawfik A. De-novo portal vein thrombosis in liver cirrhosis: risk factors and correlation with the Model for End-stage Liver Disease scoring system. Eur J Gastroenterol Hepatol. 2015;27(5):585–92.PubMedCrossRef

19.

Farrell CJ, Kirsch SH, Herrmann M. Red cell or serum folate: what to do in clinical practice? Clin Chem Lab Med. 2013;51(3):555–69 (Review).PubMedCrossRef

20.

den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost. 1998;80(6):874–7.CrossRef

21.

Langman LJ, Ray JG, Evrovski J, Yeo E, Cole DE. Hyperhomocyst(e)inemia and the increased risk of venous thromboembolism: more evidence from a case–control study. Arch Intern Med. 2000;160(7):961–4.PubMedCrossRef

22.

Obeid R, Hakki T, Jouma M, Herrmann W. The risk of venous thromboembolism associated with the factor V Leiden mutation and low B-vitamin status. Clin Chem Lab Med. 2003;41(10):1357–62.PubMedCrossRef

23.

Quéré I, Perneger TV, Zittoun J, Bellet H, Gris JC, Daurès JP, Schved JF, Mercier E, Laroche JP, Dauzat M, Bounameaux H, Janbon C, de Moerloose P. Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism: a matched case-control study. Lancet. 2002;359(9308):747–52.PubMedCrossRef

24.

Mason JB. Biomarkers of nutrient exposure and status in one-carbon (methyl) metabolism. J Nutr. 2003;133 Suppl 3(3):941S-947S.PubMedCrossRef

25.

Shane B. Folate status assessment history: implications for measurement of biomarkers in NHANES. Am J Clin Nutr. 2011;94(1):337S-342S. https://doi.org/10.3945/ajcn.111.013367.CrossRefPubMedPubMedCentral

26.

Durand P, Prost M, Loreau N, Lussier-Cacan S, Blache D. Impaired homocysteine metabolism and atherothrombotic disease. Lab Invest. 2001;81(5):645–72 (review).PubMedCrossRef

27.

Stanger O, Weger M, Renner W, Konetschny R. Vascular dysfunction in hyperhomocyst(e)inemia. Implications for atherothrombotic disease. Clin Chem Lab Med. 2001;39(8):725–33 (review).PubMedCrossRef

28.

Woo KS, Chook P, Lolin YI, Sanderson JE, Metreweli C, Celermajer DS. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. J Am Coll Cardiol. 1999;34(7):2002–6.PubMedCrossRef

29.

Stanger O, Weger M. Interactions of homocysteine, nitric oxide, folate and radicals in the progressively damaged endothelium. Clin Chem Lab Med. 2003;41(11):1444–54 (review).PubMed

30.

Walsh KA, Lewis DA, Clifford TM, et al. Risk factors for venous thromboembolism in patients with chronic liver disease. Ann Pharmacother. 2013;47(3):333–9.PubMedCrossRef

31.

Khoury T, Ayman AR, Cohen J, Daher S, Shmuel C, Mizrahi M. The complex role of anticoagulation in cirrhosis: an updated review of where we are and where we are going. Digestion. 2016;93(2):149–59.PubMedCrossRef

32.

Vivarelli M, Zanello M, Zanfi C, et al. Prophylaxis for venous thromboembolism after resection of hepatocellular carcinoma on cirrhosis: is it necessary? World J Gastroenterol. 2010;16(17):2146–50.PubMedPubMedCentralCrossRef

33.

Amitrano L, Brancaccio V, Guardascione MA, et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology. 2000;31(2):345–8.PubMedCrossRef

34.

Stanhewicz AE, Alexander LM, Kenney WL. Folic acid supplementation improves microvascular function in older adults through nitric oxide-dependent mechanisms. Clin Sci (Lond). 2015;129(2):159–67. https://doi.org/10.1042/CS20140821.CrossRef

35.

Antoniades C, Antonopoulos AS, Tousoulis D, Marinou K, Stefanadis C. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J. 2009;30(1):6–15. https://doi.org/10.1093/eurheartj/ehn515.CrossRefPubMed

36.

Antoniades C, Shirodaria C, Leeson P, Baarholm OA, Van-Assche T, Cunnington C, Pillai R, Ratnatunga C, Tousoulis D, Stefanadis C, Refsum H, Channon KM. MTHFR 677 C>T Polymorphism reveals functional importance for 5-methyltetrahydrofolate, not homocysteine, in regulation of vascular redox state and endothelial function in human atherosclerosis. Circulation. 2009;119(18):2507–15. https://doi.org/10.1161/CIRCULATIONAHA.108.808675.CrossRefPubMed

37.

Antoniades C, Tousoulis D, Stefanadis C. Nitric oxide-releasing aspirin: will it say NO to atherothrombosis? Int J Cardiol. 2007a;118(2):170–2. https://doi.org/10.1016/j.ijcard.2006.08.002.CrossRefPubMed

38.

Antoniades C, Tousoulis D, Stefanadis C. Effects of endothelial nitric oxide synthase gene polymorphisms on oxidative stress, inflammatory status, and coronary atherosclerosis: an example of a transient phenotype. J Am Coll Cardiol. 2007b;49(11):1226. https://doi.org/10.1016/j.jacc.2006.12.029(author reply 1226–7).CrossRefPubMed

39.

Ogren M, Bergqvist D, Björck M, Acosta S, Eriksson H, Sternby NH. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol. 2006;12(13):2115–9.PubMedPubMedCentralCrossRef

40.

Ho CT, Shang HS, Chang JB, Liu JJ, Liu TZ. Folate deficiency-triggered redox pathways confer drug resistance in hepatocellular carcinoma. Oncotarget. 2015;6(28):26104–18.PubMedPubMedCentralCrossRef

41.

Welzel TM, Katki HA, Sakoda LC, Evans AA, London WT, Chen G, O’Broin S, Shen FM, Lin WY, McGlynn KA. Blood folate levels and risk of liver damage and hepatocellular carcinoma in a prospective high-risk cohort. Cancer Epidemiol Biomarkers Prev. 2007;16(6):1279–82.PubMedCrossRef

42.

Choi SW, Mason JB. Folate status: effects on pathways of colorectal carcinogenesis. J Nutr. 2002;132(8 Suppl):2413S-2418S (review).PubMedCrossRef

43.

Goll MG, Bestor TH. Eukaryotic cytosine methyltransferases. Annu Rev Biochem. 2005;74:481–514 (review).PubMedCrossRef

44.

Malaguarnera G, Latteri S, Madeddu R, et al. High carbohydrate 19-9 antigen serum levels in patients with nonmelanoma skin cancer and primary occult cancer. Biomedicines. 2020;8(8):E265.PubMedCrossRef

45.

Quirk M, Kim YH, Saab S, Lee EW. Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol. 2015;21(12):3462–71.PubMedPubMedCentralCrossRef

46.

Chan SL, Chong CC, Chan AW, Poon DM, Chok KS. Management of hepatocellular carcinoma with portal vein tumor thrombosis: review and update at 2016. World J Gastroenterol. 2016;22(32):7289–300.PubMedPubMedCentralCrossRef

47.

Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.PubMedCrossRef

48.

Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4(2):439–74.PubMedPubMedCentralCrossRef

49.

Kuo CS, Lin CY, Wu MY, Lu CL, Huang RF. Relationship between folate status and tumour progression in patients with hepatocellular carcinoma. Br J Nutr. 2008;100(3):596–602.PubMedCrossRef

50.

Malaguarnera M, Catania VE, Borzì AM, Malaguarnera S, Madeddu R, Bertino G, Latteri S. Blood homocysteine levels are increased in hepatocellular carcinoma patients with portal vein thrombosis. A single center retrospective cohort study. Int J Surg Open. 2018;15:60–5.CrossRef

51.

Jacob RA, Gretz DM, Taylor PC, et al. Moderate folate depletion increases plasma homocysteine and decreases lymphocyte DNA methylation in postmenopausal women. J Nutr. 1998;128(7):1204–12.PubMedCrossRef

Titel: Folate levels in hepatocellular carcinoma patients with portal vein thrombosis
verfasst von: Giulia Malaguarnera
Vito Emanuele Catania
Saverio Latteri
Antonio Maria Borzì
Gaetano Bertino
Roberto Madeddu
Filippo Drago
Michele Malaguarnera
Publikationsdatum: 01.12.2020
Verlag: BioMed Central
Erschienen in: BMC Gastroenterology / Ausgabe 1/2020
Elektronische ISSN: 1471-230X
DOI: https://doi.org/10.1186/s12876-020-01525-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Publisher's Note

Background

Methods

Patients recruitment

Serum and whole blood folate assay

Statistical analysis

Results

Comparison from HCC patients with PVT to HCC patients without PVT

Comparison between HCC patients with PVT and controls

Comparison between HCC patients without PVT and controls (Table 3)

Discussion

Conclusion

Acknowledgements

Ethics approval and consent to participate

Consent for publication

Competing interests

Publisher's Note

Weitere Artikel der Ausgabe 1/2020

HBsAg quantification predicts off-treatment response to interferon in chronic hepatitis B patients: a retrospective study of 250 cases

Narrow-band imaging and high-definition white-light endoscopy in patients with serrated lesions not fulfilling criteria for serrated polyposis syndrome: a randomized controlled trial with tandem colonoscopy

Jejunogastric intussusception after Whipple procedure with B-II reconstruction: a case report

A rare case of Epstein–Barr virus-positive mucocutaneous ulcer that developed into an intestinal obstruction: a case report

Gastroesophageal reflux disease in a typical African population: a symptom-based multicenter study

Validation of a new prognostic model to predict short and medium-term survival in patients with liver cirrhosis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Update Innere Medizin